trending Market Intelligence /marketintelligence/en/news-insights/trending/0wllcl42mNUNcJTr_io_Dw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

UnitedHealth's Optum, DaVita agree to cut price of medical group deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

Part Two IFRS 9 Blog Series: The Need to Upgrade Analytical Tools

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

UnitedHealth's Optum, DaVita agree to cut price of medical group deal

UnitedHealth Group Inc.'s Optum and DaVita Inc. have agreed to cut the sale price of DaVita Medical Group to $4.34 billion.

Optum was initially slated to pay $4.90 billion for the business, which will be combined with its OptumCare division. But Optum and DaVita have agreed to amend their equity purchase agreement to lower the sale price due to underlying business performance and in order to acquire the Federal Trade Commission's approval.

The FTC approval is the final remaining regulatory approval necessary to close the transaction. On Nov. 28, the California Department of Managed Health Care approved the proposed transaction. The companies expect to close the transaction in the first quarter of 2019.

As a result of the change in sale price, DaVita expects to record a charge in the fourth quarter of about $200 million to $250 million.